REGENERON PHARMACEUTICALS, INC.【REGN】Cash flow
Market cap
$86B
P/E ratio
| 2010/12 | 2011/12 | 2012/12 | 2013/12 | 2014/12 | 2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | |
| Depreciation & amortization | 20 | - | 37 | 41 | 53 | 75 | 105 | 145 | 148 | 210 | 236 | 286 | 341 | 421 | 483 |
| Stock-based compensation | 40 | 56 | 94 | 198 | 307 | 459 | 560 | 507 | 427 | 464 | 432 | 602 | 725 | 885 | 983 |
| Cash from operations | 96 | -142 | -75 | 584 | 743 | 1,331 | 1,473 | 1,307 | 2,195 | 2,430 | 2,618 | 7,081 | 5,015 | 4,594 | 4,421 |
| Capital expenditures | -100 | -57 | -49 | -156 | -333 | -678 | -512 | -273 | -383 | -430 | -615 | -552 | -590 | -719 | -756 |
| Cash from investing | -434 | 128 | -81 | -355 | -421 | -908 | -1,047 | -1,005 | -1,463 | -2,028 | -71 | -5,385 | -3,785 | -3,185 | -2,468 |
| Repurchases of common stock | - | - | - | - | - | - | - | - | 4 | 276 | 5,847 | 1,645 | 2,083 | 2,235 | 2,603 |
| Proceeds from issuance of term debt, net | - | - | - | - | - | - | - | - | - | - | 1,982 | - | - | - | - |
| Cash from financing | 243 | 384 | -98 | 77 | -209 | -263 | -700 | -24 | -77 | -252 | -1,970 | -1,006 | -1,009 | -1,790 | -2,200 |
| Free cash flow | |||||||||||||||
| FCF margin (%) |